<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02088021</url>
  </required_header>
  <id_info>
    <org_study_id>CL07045</org_study_id>
    <nct_id>NCT02088021</nct_id>
  </id_info>
  <brief_title>Assessment of the St. Jude Medical PorticoTM Re-sheathable Aortic Valve System - Alternative Access</brief_title>
  <acronym>PorticoALTEU</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical investigation is to evaluate the use of the Portico ALC Delivery&#xD;
      System to place a transcatheter aortic valve through an alternative access site, specifically&#xD;
      subclavian/axillary or TAo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Business decision&#xD;
  </why_stopped>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Vascular Complications related to the Portico ALC Delivery System</measure>
    <time_frame>30 day post procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>30 day post procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event Rates</measure>
    <time_frame>30 days post procedure</time_frame>
    <description>Event rates as described by VARC-2&#xD;
&quot;Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document European Heart Journal (2012) 33, 2403-2418.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional improvement from baseline</measure>
    <time_frame>30 days post procedure</time_frame>
    <description>Functional improvement from baseline as compared to 30 days by:&#xD;
NYHA Functional Classification&#xD;
Six Minute Walk Test&#xD;
Effective Orifice Area (EOA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute device success</measure>
    <time_frame>12 months post procedure</time_frame>
    <description>Acute device success defined as:&#xD;
Ability of the Portico ALC Delivery System to successfully deliver, deploy, and resheath (if necessary) a transcatheter aortic valve&#xD;
Absence of procedural mortality&#xD;
Correct positioning of a single prosthetic heart valve into the proper anatomical location&#xD;
Intended performance of the prosthetic heart valve, as defined by:&#xD;
mean aortic valve gradient &lt;20 mmHg or peak velocity &lt;3 m/s, and&#xD;
no moderate or severe prosthetic valve regurgitation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Symptomatic Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>Portico Transcatheter Aortic Valve Implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placement of the SJM Portico aortic valve with a ALC delivery system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Portico Transcatheter Aortic Valve</intervention_name>
    <description>Placement of the SJM Portico aortic valve with a ALC delivery system</description>
    <arm_group_label>Portico Transcatheter Aortic Valve Implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has provided written informed consent.&#xD;
&#xD;
          -  Subject is 65 years of age or older at the time of index procedure, and/or has&#xD;
             comorbidities that, in the opinion of the Principal Investigator or the Subject&#xD;
             Selection Committee, preclude surgical valve replacement.&#xD;
&#xD;
          -  Subject's aortic annulus diameter meets the range indicated in the Instructions for&#xD;
             Use as measured by multislice CT conducted within 120 days prior to the index&#xD;
             procedure.&#xD;
&#xD;
          -  Subject has senile degenerative aortic stenosis with echocardiography within 30 days&#xD;
             of index procedure as defined by at least 1 of the following:&#xD;
&#xD;
               -  derived mean gradient greater than 40 mmHg, OR&#xD;
&#xD;
               -  jet velocity greater than 4.0 m/s, OR&#xD;
&#xD;
               -  aortic valve area of less than 0.8 cm2, OR&#xD;
&#xD;
               -  aortic valve area index less than or equal to 0.6 cm2/m2.&#xD;
&#xD;
          -  Subject has symptomatic aortic stenosis as demonstrated by NYHA Functional&#xD;
             Classification of II, III, or IV.&#xD;
&#xD;
          -  Subject is deemed high operable risk and delivery route is suitable for TAVI per the&#xD;
             medical opinion of the Subject Selection Committee.&#xD;
&#xD;
          -  Subject's predicted operative mortality or serious, irreversible morbidity risk is&#xD;
             less than 50% at 30 days post index procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is unwilling or unable to comply with all study-required follow-up&#xD;
             evaluations.&#xD;
&#xD;
          -  Subject has a documented history of a cerebral vascular accident (CVA) or transient&#xD;
             ischemic attack (TIA) within 6 months (less than or equal to 180 days) prior to the&#xD;
             index procedure.&#xD;
&#xD;
          -  Subject has carotid artery disease requiring intervention.&#xD;
&#xD;
          -  Evidence of an acute myocardial infarction (MI) within 30 days prior to patient&#xD;
             providing consent (defined as: ST Segment Elevation as evidenced on 12 Lead ECG).&#xD;
&#xD;
          -  Subject has a native aortic valve that is congenitally unicuspid, bicuspid,&#xD;
             quadricuspid or non-calcified as seen by echocardiography.&#xD;
&#xD;
          -  Subject has mitral valvular regurgitation greater than grade III.&#xD;
&#xD;
          -  Subject has moderate or severe mitral stenosis.&#xD;
&#xD;
          -  Subject has a pre-existing prosthetic cardiac device, valve, or prosthetic ring in any&#xD;
             position.&#xD;
&#xD;
          -  Subject refuses any blood product transfusion.&#xD;
&#xD;
          -  Subject refuses surgical valve replacement.&#xD;
&#xD;
          -  Subject has left ventricular ejection fraction (LVEF) less than 20%.&#xD;
&#xD;
          -  Subject has documented, untreated symptomatic coronary artery disease (CAD) requiring&#xD;
             revascularization.&#xD;
&#xD;
          -  Subject has had a percutaneous interventional or other invasive cardiovascular or&#xD;
             peripheral vascular procedure less than or equal to 14 days of index procedure.&#xD;
&#xD;
          -  Subject has severe basal septal hypertrophy that would interfere with transcatheter&#xD;
             aortic valve placement.&#xD;
&#xD;
          -  Subject has a history of, or is currently diagnosed with endocarditis.&#xD;
&#xD;
          -  There is imaging evidence of intracardiac mass, thrombus, or vegetation.&#xD;
&#xD;
          -  Subject is considered hemodynamically unstable (requiring inotropic support or&#xD;
             mechanical heart assistance).&#xD;
&#xD;
          -  Subject is in acute pulmonary edema or requiring intravenous diuretic therapy to&#xD;
             stabilize heart failure.&#xD;
&#xD;
          -  Subject with significant pulmonary disease as determined and documented by the&#xD;
             Investigator.&#xD;
&#xD;
          -  Subject has significant chronic steroid use as determined and documented by the&#xD;
             Investigator.&#xD;
&#xD;
          -  Subject has a documented hypersensitivity or contraindication to anticoagulant or&#xD;
             antiplatelet medication.&#xD;
&#xD;
          -  Subject has renal insufficiency as evidenced by a serum creatinine greater than 3.0&#xD;
             mg/dL (265.5 Âµmol/L) or end-stage renal disease requiring chronic dialysis.&#xD;
&#xD;
          -  Subject has morbid obesity defined as a BMI greater than or equal to 40.&#xD;
&#xD;
          -  Subject has ongoing infection or sepsis.&#xD;
&#xD;
          -  Subject has blood dyscrasias (eg, leukopenia, acute anemia, thrombocytopenia, history&#xD;
             of bleeding diathesis, or coagulopathy).&#xD;
&#xD;
          -  Subject has a current autoimmune disease that, in the opinion of the Principal&#xD;
             Investigator or the Subject Selection Committee, precludes the subject from study&#xD;
             participation.&#xD;
&#xD;
          -  Significant ascending aortic disease documented by diameter greater than 40mm.&#xD;
&#xD;
          -  Subject has an active peptic ulcer or has had gastrointestinal (GI) bleeding within 90&#xD;
             days prior to the index procedure.&#xD;
&#xD;
          -  Subject is currently participating in another investigational drug or device study.&#xD;
&#xD;
          -  Subject requires emergency surgery for any reason.&#xD;
&#xD;
          -  Subject has a life expectancy less than 12 months.&#xD;
&#xD;
          -  Subject has other medical, social or psychological conditions that, in the opinion of&#xD;
             the Principal Investigator or the Subject Selection Committee, preclude the subject&#xD;
             from study participation.&#xD;
&#xD;
          -  Subject is diagnosed with dementia or admitted to a chronic care facility which would&#xD;
             fundamentally complicate rehabilitation from the procedure or compliance with&#xD;
             follow-up visits.&#xD;
&#xD;
          -  Subject is unwilling or unable to comply with all study-required follow-up&#xD;
             evaluations.&#xD;
&#xD;
          -  Subject has a documented history of a cerebral vascular accident (CVA) or transient&#xD;
             ischemic attack (TIA) within 6 months (less than or equal to 180 days) prior to the&#xD;
             index procedure.&#xD;
&#xD;
          -  Subject has carotid artery disease requiring intervention.&#xD;
&#xD;
          -  Evidence of an acute myocardial infarction (MI) within 30 days prior to patient&#xD;
             providing consent (defined as: ST Segment Elevation as evidenced on 12 Lead ECG).&#xD;
&#xD;
          -  Subject has a native aortic valve that is congenitally unicuspid, bicuspid,&#xD;
             quadricuspid or non-calcified as seen by echocardiography.&#xD;
&#xD;
          -  Subject has mitral valvular regurgitation greater than grade III.&#xD;
&#xD;
          -  Subject has moderate or severe mitral stenosis.&#xD;
&#xD;
          -  Subject has a pre-existing prosthetic cardiac device, valve, or prosthetic ring in any&#xD;
             position.&#xD;
&#xD;
          -  Subject refuses any blood product transfusion.&#xD;
&#xD;
          -  Subject refuses surgical valve replacement.&#xD;
&#xD;
          -  Subject has left ventricular ejection fraction (LVEF) less than 20%.&#xD;
&#xD;
          -  Subject has documented, untreated symptomatic coronary artery disease (CAD) requiring&#xD;
             revascularization.&#xD;
&#xD;
          -  Cardiovascular or peripheral vascular procedure less than or equal to 14 days of index&#xD;
             procedure.&#xD;
&#xD;
          -  Subject has severe basal septal hypertrophy that would interfere with transcatheter&#xD;
             aortic valve placement.&#xD;
&#xD;
          -  Subject has a history of, or is currently diagnosed with endocarditis.&#xD;
&#xD;
          -  There is imaging evidence of intracardiac mass, thrombus, or vegetation.&#xD;
&#xD;
          -  Subject is considered hemodynamically unstable (requiring inotropic support or&#xD;
             mechanical heart assistance).&#xD;
&#xD;
          -  Subject is in acute pulmonary edema or requiring intravenous diuretic therapy to&#xD;
             stabilize heart failure.&#xD;
&#xD;
          -  Subject with significant pulmonary disease as determined and documented by the&#xD;
             Investigator.&#xD;
&#xD;
          -  Subject has significant chronic steroid use as determined and documented by the&#xD;
             Investigator.&#xD;
&#xD;
          -  Subject has a documented hypersensitivity or contraindication to anticoagulant or&#xD;
             antiplatelet medication.&#xD;
&#xD;
          -  Subject has renal insufficiency as evidenced by a serum creatinine greater than 3.0&#xD;
             mg/dL (265.5 Âµmol/L) or end-stage renal disease requiring chronic dialysis.&#xD;
&#xD;
          -  Subject has morbid obesity defined as a BMI greater than or equal to 40.&#xD;
&#xD;
          -  Subject has ongoing infection or sepsis.&#xD;
&#xD;
          -  Subject has blood dyscrasias (eg, leukopenia, acute anemia, thrombocytopenia, history&#xD;
             of bleeding diathesis, or coagulopathy).&#xD;
&#xD;
          -  Significant ascending aortic disease documented by diameter greater than 40mm.&#xD;
&#xD;
          -  Subject has an active peptic ulcer or has had gastrointestinal (GI) bleeding within 90&#xD;
             days prior to the index procedure.&#xD;
&#xD;
          -  Subject is currently participating in another investigational drug or device study.&#xD;
&#xD;
          -  Subject requires emergency surgery for any reason.&#xD;
&#xD;
          -  Subject has a life expectancy less than 12 months.&#xD;
&#xD;
          -  Subject has other medical, social or psychological conditions that, in the opinion of&#xD;
             the Principal Investigator or the Subject Selection Committee, preclude the subject&#xD;
             from study participation.&#xD;
&#xD;
          -  Subject is diagnosed with dementia or admitted to a chronic care facility which would&#xD;
             fundamentally complicate rehabilitation from the procedure or compliance with&#xD;
             follow-up visits.&#xD;
&#xD;
          -  Subject has a documented allergy to contrast media, nitinol alloys, porcine tissue, or&#xD;
             bovine tissue.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Axel Linke, Prof Dr. med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart Center Leipzig - University Hospital</affiliation>
  </overall_official>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>March 4, 2014</study_first_submitted>
  <study_first_submitted_qc>March 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2014</study_first_posted>
  <last_update_submitted>February 1, 2019</last_update_submitted>
  <last_update_submitted_qc>February 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

